These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31131591)

  • 21. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.
    Giancola SE; Mahoney MV; Hogan MD; Raux BR; McCoy C; Hirsch EB
    Chemotherapy; 2017; 62(2):100-104. PubMed ID: 27788499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.
    Patwardhan V; Singh S
    Int Urol Nephrol; 2017 Sep; 49(9):1637-1643. PubMed ID: 28616818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against
    Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Roberts JA; Mouton JW; Peleg AY
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria.
    Wangchinda W; Rattanaumpawan P
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35951643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
    J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
    Li G; Standing JF; Bielicki J; Hope W; van den Anker J; Heath PT; Sharland M
    Drugs; 2017 Jun; 77(9):941-950. PubMed ID: 28456943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
    Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Rates of Fosfomycin Resistance in Gram-Negative Urinary Isolates from Israel.
    Peretz A; Naamneh B; Tkhawkho L; Nitzan O
    Microb Drug Resist; 2019 Apr; 25(3):408-412. PubMed ID: 30724694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fosfomycin: A Revisited Antibiotic for Urinary Tract Infections.
    Parikh FS
    J Assoc Physicians India; 2017 Sep; 65(9):11. PubMed ID: 29313569
    [No Abstract]   [Full Text] [Related]  

  • 35. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options.
    Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM
    Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.
    Babiker A; Clarke L; Doi Y; Shields RK
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114856. PubMed ID: 31307867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
    Rouphael N; Winokur P; Keefer MC; Traenkner J; Drobeniuc A; Doi Y; Munsiff S; Fowler VG; Evans S; Oler RE; Tuyishimire B; Lee M; Ghazaryan V; Chambers HF;
    mBio; 2023 Oct; 14(5):e0167723. PubMed ID: 37698412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fosfomycin for treatment of uncomplicated lower urinary tract infection].
    Al-Shukri SH; Slesarevskaya MN; Kuzmin IV
    Urologiia; 2018 Dec; (5):153-158. PubMed ID: 30575367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?
    Cai T; Cocci A; Verze P; Rizzo M; Palmieri A; Liguori G; Trombetta C; Adembri C; Carini M; Bartoletti R; Wagenlehner FM; Bonkat G; Mirone V; Bjerklund Johansen TE; Novelli A
    J Chemother; 2018 Sep; 30(5):290-295. PubMed ID: 30843774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fosfomycin in the pediatric setting: Evidence and potential indications.
    Baquero-Artigao F; Del Rosal Rabes T
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):55-61. PubMed ID: 31131593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.